HLS Therapeutics (HLS) Aktienübersicht
HLS Therapeutics Inc. ist ein Spezialpharmaunternehmen, das pharmazeutische Produkte zur Behandlung von psychiatrischen Störungen, des zentralen Nervensystems und von Herz-Kreislauf-Erkrankungen in Kanada, den Vereinigten Staaten und international erwirbt und vertreibt. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
HLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HLS Therapeutics Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | CA$4.35 |
| 52-Wochen-Hoch | CA$5.77 |
| 52-Wochen-Tief | CA$4.22 |
| Beta | 0.85 |
| 1 Monat Veränderung | -7.25% |
| 3 Monate Veränderung | 1.87% |
| 1 Jahr Veränderung | -12.12% |
| 3 Jahre Veränderung | -30.29% |
| 5 Jahre Veränderung | -75.47% |
| Veränderung seit IPO | -62.47% |
Aktuelle Nachrichten und Updates
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Recent updates
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.HLS: Future Upside Will Depend On Executing Refined Earnings Outlook
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company that feed into revised assumptions regarding growth, margins and future P/E. Analyst Commentary Recent research updates on HLS Therapeutics show price targets aligning at CA$4.45, with ratings maintained rather than shifted to more negative stances.HLS: Future Execution Risks Will Temper Benefits Of New Cholesterol Franchise
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on its growth profile and profitability. Analyst Commentary Bearish analysts are signaling a more cautious stance on HLS Therapeutics after the revised CA$4.45 price target.HLS: Future Execution Risks Will Offset New Product And Margin Assumptions
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company’s revenue growth potential, profit margin outlook, and a higher assumed future P/E multiple. Analyst Commentary Bearish analysts have reacted to recent developments by trimming their price target on HLS Therapeutics to CA$4.45 from CA$4.75, while maintaining a Hold stance.HLS: Future Share Performance Will Rely On Execution Against Updated Outlook
The analyst price target for HLS Therapeutics has been reduced by CA$0.30 to CA$4.45. Analysts cited updated assumptions around growth, profitability and valuation multiples as key drivers for the change.HLS: Fair Outlook Will Balance Revised Profitability Assumptions And Execution Risks
Analysts have trimmed their price target on HLS Therapeutics to CA$4.72 from CA$4.76, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a slightly lower future P/E multiple. Valuation Changes Fair Value: CA$ fair value estimate adjusted slightly from CA$4.76 to CA$4.72.HLS: Improved Profitability Outlook Will Support Stronger Future Share Performance
Analysts now see fair value for HLS Therapeutics at about CA$11.59, slightly below the prior CA$11.79. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.HLS: Higher Profitability Outlook Will Support Upgraded Future Share Performance
Analysts have nudged their price target on HLS Therapeutics higher to C$7 from C$6, pointing to updated assumptions on revenue growth, profit margins and future P/E levels that support a slightly revised outlook for the shares. Analyst Commentary Recent Street research reflects a slightly more optimistic tone around HLS Therapeutics, with bullish analysts adjusting their models to support a higher valuation anchor for the shares.HLS: Higher Profitability Outlook Will Drive Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics to C$7 from C$6, reflecting updated views on fair value, growth expectations, profitability, and future P/E assumptions. Analyst Commentary Recent Street research points to a more constructive view on HLS Therapeutics, with bullish analysts revisiting their assumptions on fair value, growth potential, and what they are willing to pay on a P/E basis.HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Analysts lifted their price target for HLS Therapeutics to C$7 from C$6, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and a lower future P/E multiple in their models. Analyst Commentary Even with the price target now set at C$7, some research commentary still reads as cautious.HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics by C$1 to C$7, reflecting higher projected fair value, faster expected revenue growth, and improved profit margin assumptions, despite a slightly higher discount rate and lower future P/E multiple. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in HLS Therapeutics execution and earnings trajectory, even after factoring in a modestly higher risk profile.
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
The analysts might have been a bit too bullish on HLS Therapeutics Inc. ( TSE:HLS ), given that the company fell short...Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.42 Current share...Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
It's not a stretch to say that HLS Therapeutics Inc.'s ( TSE:HLS ) price-to-sales (or "P/S") ratio of 1.5x right now...Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
It's shaping up to be a tough period for HLS Therapeutics Inc. ( TSE:HLS ), which a week ago released some...After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
The HLS Therapeutics Inc. ( TSE:HLS ) share price has done very well over the last month, posting an excellent gain of...Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Market forces rained on the parade of HLS Therapeutics Inc. ( TSE:HLS ) shareholders today, when the analysts...Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...Aktionärsrenditen
| HLS | CA Pharmaceuticals | CA Markt | |
|---|---|---|---|
| 7D | -2.0% | 6.9% | -2.5% |
| 1Y | -12.1% | 80.2% | 30.6% |
Rendite im Vergleich zur Industrie: HLS unter dem Niveau der Branche Canadian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 80.2% erzielte.
Rendite vs. Markt: HLS hinter dem Markt Canadian zurück, der im vergangenen Jahr eine Rendite von 30.6 erzielte.
Preisvolatilität
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.8% |
Stabiler Aktienkurs: HLS hatte in den letzten 3 Monaten im Vergleich zum Canadian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: HLSDie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
HLS Therapeutics Inc. ist ein Spezialpharmaunternehmen, das pharmazeutische Produkte zur Behandlung von psychiatrischen Erkrankungen, des zentralen Nervensystems und von Herz-Kreislauf-Erkrankungen in Kanada, den Vereinigten Staaten und international erwirbt und vermarktet. Zu den wichtigsten Produkten des Unternehmens gehören Clozaril, ein atypisches Antipsychotikum zur Behandlung der Symptome von behandlungsresistenter Schizophrenie, und Vascepa, ein Icosapent-Ethyl-Kapselpräparat zur Behandlung von Herz-Kreislauf-Erkrankungen. Darüber hinaus vertreibt das Unternehmen MyCare Psychiatry Lab Assays und MyCare Insite, ein Point-of-Care-Gerät zur Messung der Medikamentenspiegel von Patienten.
HLS Therapeutics Inc.'s Grundlagenzusammenfassung
| HLS grundlegende Statistiken | |
|---|---|
| Marktanteil | CA$137.92m |
| Gewinn(TTM) | -CA$14.35m |
| Umsatz(TTM) | CA$77.74m |
Ist HLS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| HLS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$55.74m |
| Kosten der Einnahmen | US$16.15m |
| Bruttogewinn | US$39.59m |
| Sonstige Ausgaben | US$49.89m |
| Gewinn | -US$10.29m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.33 |
| Bruttomarge | 71.03% |
| Nettogewinnspanne | -18.46% |
| Schulden/Eigenkapital-Verhältnis | 73.5% |
Wie hat sich HLS auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/09 19:04 |
| Aktienkurs zum Tagesende | 2026/06/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
HLS Therapeutics Inc. wird von 4 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |